These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21770080)

  • 21. Off-label prescribing. Legal implications.
    Henry V
    J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
    [No Abstract]   [Full Text] [Related]  

  • 22. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirements for FDA-approved patient information spelled out in final rule.
    Am J Health Syst Pharm; 1999 Jan; 56(2):107-8. PubMed ID: 10030523
    [No Abstract]   [Full Text] [Related]  

  • 24. Physicians, pharmacists, pharmaceutical manufacturers: partners in patient care, partners in litigation?
    Willig SH
    Spec Law Dig Health Care (Mon); 1987 Feb; 8(12):7-40. PubMed ID: 10280590
    [No Abstract]   [Full Text] [Related]  

  • 25. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
    Anthony M; Romero K; Malone DC; Hines LE; Higgins L; Woosley RL
    Clin Pharmacol Ther; 2009 Oct; 86(4):425-9. PubMed ID: 19587643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
    Huh J; Cude BJ
    J Health Commun; 2004; 9(6):529-40. PubMed ID: 15764451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Communicating with patients about their medications.
    Kessler DA
    N Engl J Med; 1991 Dec; 325(23):1650-2. PubMed ID: 1944456
    [No Abstract]   [Full Text] [Related]  

  • 28. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C; Guglielmo BJ
    Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceutical inserts: legal consequences.
    Hirsh HL
    Hosp Med Staff; 1979 Jul; 8(7):2-6. PubMed ID: 10242674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 31. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
    Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 33. Increasing the odds of patient compliance through prescription warning labels.
    Ferguson JM; Discenza R; Miller JA
    J Health Care Mark; 1987 Mar; 7(1):37-46. PubMed ID: 10281382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-label prescribing and the standard of care.
    Johnson LJ
    Med Econ; 2001 Aug; 78(16):97. PubMed ID: 11550443
    [No Abstract]   [Full Text] [Related]  

  • 35. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug information leaflets for consumers need improvement, FDA says.
    Traynor K
    Am J Health Syst Pharm; 2002 Aug; 59(16):1498, 1501. PubMed ID: 12185823
    [No Abstract]   [Full Text] [Related]  

  • 37. Prescription drug product labeling; medication guide requirements--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(230):66378-400. PubMed ID: 10338877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA delays proposal on patient drug information.
    Am J Health Syst Pharm; 1995 Feb; 52(4):355-6. PubMed ID: 7757853
    [No Abstract]   [Full Text] [Related]  

  • 39. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
    Weeks EA
    Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA electronic drug labels to improve patient safety.
    J Pain Palliat Care Pharmacother; 2006; 20(2):96-7. PubMed ID: 16789334
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.